In an era where cancer survival rates are steadily improving thanks to remarkable advances in oncologic therapies, a new clinical frontier is emerging that bridges oncology and nephrology: onconephrology. This rapidly developing subspecialty addresses the intricate and often under-recognized challenges faced by patients who battle both cancer and kidney disease. As treatments such as immunotherapy, traditional chemotherapies, and stem cell transplants gain prominence, their impact on renal health becomes a pivotal concern. Recognizing this critical intersection, researchers Dr. Raad B. Chowdhury and Dr. Shruti Gupta from the Division of Nephrology at Brigham and Women’s Hospital (BWH) have led an innovative effort to transform kidney care for cancer patients by establishing a dedicated inpatient onconephrology consult service.
This pioneering program, based at one of the world’s foremost academic medical centers within the Mass General Brigham healthcare system, represents a paradigm shift in managing kidney complications in oncologic settings. Previously, individuals suffering from complications such as acute kidney injury were managed under the general nephrology consult service, which lacked specialization in oncologic renal pathophysiology. The new onconephrology service specifically focuses on the dynamic renal manifestations of cancer and anticancer therapies, integrating state-of-the-art nephrology expertise with an in-depth understanding of oncology-related kidney insults.
The origin of this novel service is attributed in large part to Dr. Shruti Gupta, who also founded the American Society of Onconephrology (ASON) and acted as its inaugural president. Dr. Chowdhury currently serves as vice president. This society has grown to include members from fourteen countries worldwide, underscoring the global recognition of onconephrology as an indispensable field. At BWH, the team including co-first author Jessica Ortega meticulously documented their experience through a case study that was recently published in the Clinical Journal of the American Society of Nephrology.
The study provides invaluable insights into the establishment of the inpatient consult service, detailing its organizational framework, consultation pathways, and preliminary clinical outcomes observed in its inaugural year. The authors executed a comprehensive manual review contrasting data from July 2022 through June 2023—when oncology teams referred patients to the general nephrology service—with data between July 2023 and June 2024 after the onconephrology service’s inception. This comparison elucidated the tangible benefits of specialized nephrology care focused on cancer patients.
Notably, the findings revealed that patients with cancer-associated acute kidney injury managed by the onconephrology consult service demonstrated significantly higher rates of kidney recovery at hospital discharge compared to those treated by general nephrology. This suggests that domain-specific knowledge and tailored protocols implemented by onconephrologists can directly influence renal outcomes amid complex oncologic care. In contrast, the study observed no significant difference between groups concerning sodium level corrections, indicating the nuanced spectrum of renal-electrolyte disturbances in these patients.
The impact of the service extended beyond patient outcomes, as the research team conducted anonymous surveys of oncologists and advanced practice providers who frequently collaborate with nephrology specialists. An overwhelming majority—81%—found the dedicated onconephrology service beneficial, while 88% expressed strong inclination to utilize it again for future patients. This high degree of satisfaction highlights the critical role of specialized consultative services in multidisciplinary cancer care, facilitating seamless communication, and integrated treatment planning.
Importantly, the formation of the inpatient onconephrology team has also facilitated smoother transitions from hospital admission to outpatient follow-up, enabling longitudinal care that is attuned to the evolving renal needs of oncology patients. This continuum is essential because kidney complications often persist or emerge anew post-discharge, necessitating ongoing vigilance and management. The study thus sets a new benchmark for comprehensive onconephrology practices in inpatient and outpatient settings.
The methodologies applied in this case study were rigorous and clinically grounded. Manual chart reviews were performed to extract detailed patient data, focusing on parameters that reflect renal function recovery, electrolyte imbalances such as hyponatremia, and other key clinical endpoints pertinent to kidney disease in cancer. Such granularity in data collection ensures that observed differences in outcomes are attributable to the specialized nature of the consult service rather than confounding variables.
Looking forward, Drs. Chowdhury and Gupta emphasize the need for larger, multicenter studies employing more robust, prospective designs to evaluate causal effects and long-term outcomes comprehensively. Exploring the mechanisms by which onconephrology interventions improve kidney recovery will be critical in refining care protocols. Moreover, deepening collaborations between nephrologists and oncologists remains a top priority to proactively identify at-risk patients and tailor cancer therapies that minimize nephrotoxicity without compromising oncologic efficacy.
The inception of this inpatient onconephrology consult service is a leap toward personalized medicine in complex patients grappling with the dual burden of cancer and kidney disease. It underscores the importance of subspecialty integration and innovation in healthcare to confront multifaceted clinical challenges. While the promise of oncologic advances brings hope for longer survival, the accompanying risk of kidney complications demands vigilant, specialized management to preserve renal health and optimize overall patient outcomes.
This study, published online in April 2025 in the Clinical Journal of the American Society of Nephrology, not only provides a blueprint for institutions worldwide to replicate similar services but also fuels a nascent movement toward establishing onconephrology as a recognized subspecialty deserving of dedicated clinical and research focus. The Mass General Brigham system continues to lead the charge in merging academic excellence with compassionate, innovative care tailored to modern complexities in medicine.
Subject of Research: People
Article Title: Innovating Kidney Care in Patients with Cancer: The Development of an Inpatient Onconephrology Service
News Publication Date: 15-Apr-2025
Web References:
https://doi.org/10.2215/cjn.0000000714
https://www.massgeneralbrigham.org/en
https://www.ason-online.org/
References:
Chowdhury RB, Ortega JL, Wells SL, et al. Innovating Kidney Care in Patients with Cancer: The Development of an Inpatient Onconephrology Service. Clin J Am Soc Nephrol. Published online March 19, 2025. doi:10.2215/CJN.0000000714
Keywords: Kidney, Cancer patients
Tags: acute kidney injury in cancer patientsBrigham and Women’s Hospital researchcancer survivorship and kidney diseasecancer treatment and renal healthimmunotherapy impact on kidneysinnovative kidney management strategiesinterdisciplinary approaches in medical carekidney care for cancer patientsnephrology and oncology integrationoncology-related renal complicationsonconephrology advancementsspecialized kidney services for oncology
